IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
The deal covers IncellDx's portfolio of immune-oncology & oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells & immune cell subtypes.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.
The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.
The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.